Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 21 of 25, showing 5 Applications out of 121 total, starting on record 101, ending on 105

# Protocol No Study Title Investigator(s) & Site(s)

101.

ECCT/15/11/04   VAC040
    A Phase 1/2, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Tolerability, and Immunogenicity of Stretococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide (PATH-wSP) in Healthy Kenya Young Adults (18 - 40years) and Toddlers (12 - 19months)   
Principal Investigator(s)
1. John Anthony Gerard Scott
Site(s) in Kenya
KEMRI-Wellcome Trust Research Program
 
View

102.

ECCT/15/06/04   A5316
        A5316           Evaluating Pharmacokinetic Interactions with Vaginal Ring Contraceptives and Antiretroviral Therapy   
Principal Investigator(s)
1. Dr. Esther Mumbi Makanga Makanga
2. Dr. Victor Akelo Akelo
3. Dr.Victor O. Mudhune Mudhune
4. Dr. Kevin P. Cain Cain
Site(s) in Kenya
KEMRI- CDC
 
View

103.

ECCT/15/05/01   Janssen Ebola vaccine study
    A Randomized, Observer-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults, Including Elderly Subjects, HIV-infected Subjects, and Healthy Children in Two Age Strata in Africa   
Principal Investigator(s)
1. Prof Omu Aggrey Anzala
Site(s) in Kenya
KAVI –Institute of Clinical Research
 
View

104.

ECCT/15/02/05  
    An open-label clinical trial to assess the pharmacokinetics and safety of miltefosine allometric dose for the treatment of children with primary visceral leishmaniasis in Eastern Africa   
Principal Investigator(s)
1. Rashid Juma
Site(s) in Kenya
1. Kimalel Health Centre (Baringo county)
2. Kacheliba District Hospital (West Pokot county)
 
View

105.

ECCT/14/11/02   A5297
    An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium falciparum Subclinical Parasitemia in HIV-infected Adults with CD4+ Counts >200 and < 500 cells/mm3   
Principal Investigator(s)
1. VICTOR AKELO
Site(s) in Kenya
KEMRI/CDC CLINICAL RESEARCH CENTRE
 
View